ArticleLung India : official organ of Indian Chest Society2026
Unveiling MicroRNA-21 as a non-invasive diagnostic biomarker in chronic obstructive pulmonary disease-associated pulmonary hypertension: Comparative insights with NT-proBNP.
Article in Lung India : official organ of Indian Chest Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perfect diagnostic accuracy in a small derivation cohort and outdated classification criteria: Methodological concerns regarding miR-21 as a biomarker for chronic obstructive pulmonary disease-associated pulmonary hypertension.Lung India : official organ of Indian Chest Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary hypertension (PH) is a fatal complication of chronic obstructive pulmonary disease (COPD) that worsens its prognosis. However, the associated diagnostic markers are uncertain. We assess the diagnostic utility of microRNA-21 (miR-21) and NT-proBNP for PH diagnosis in COPD patients.
methodsWe selected three groups of participants: Group 1 consisted of 25 patients with COPD who did not have PH (COPD); Group 2 included 35 patients with COPD and PH (COPD-PH); and Group 3 comprised 30 healthy controls. Demographic, spirometric, echocardiographic-Doppler study, and biochemical variables were recorded and compared among these three groups. Serum miR-21 was measured by quantitative real-time PCR.
resultsSerum miR-21 level in COPD-PH patients was significantly higher compared with that in COPD patients and controls (P < 0.001). Compared with the COPD group, the COPD-PH group had greater miR-21 and brain natriuretic peptide (BNP) levels but significantly reduced forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), tricuspid annular plane systolic excursion (TAPSE), 6-minute walk test, and right ventricular (RV) functional parameters. Receiver Operating Characteristic curve analysis revealed that miRNA-21 had good diagnostic value for PH diagnosis in COPD patients, with an area under the curve (AUC) of 1.000, 100% sensitivity, and 100% specificity at a cutoff >7.94. While NT-proBNP demonstrated good accuracy, with an AUC of 0.936, sensitivity of 88.6%, and specificity of 88% at a cutoff >390.1 pg/mL.
conclusionmiR-21 may serve as a useful and reliable biomarker for diagnosing PH in COPD patients, outperforming the traditional biomarker NT-proBNP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.